{"id":"NCT00355199","sponsor":"Gruppo Italiano Terapie Innovative nei Linfomi","briefTitle":"Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.","officialTitle":"Multicentric Randomized Phase III Study Comparing High Doses of Chemotherapy With Rituximab Followed by Auto-transplant HPC Versus CHOP Plus Rituximab as First Line Therapy in High Risk Patients With DLBCL Non-Hodgkin's Lymphomas","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-05","primaryCompletion":"2013-03","completion":"2013-03","firstPosted":"2006-07-21","resultsPosted":"2017-08-10","lastUpdate":"2017-08-10"},"enrollment":246,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diffuse Large B-Cell Lymphoma"],"interventions":[{"type":"DRUG","name":"Rituximab-HDS","otherNames":["Rituximab supplemented high-dose sequential chemotherapy."]},{"type":"DRUG","name":"Rituximab-CHOP","otherNames":["Rituximab/Cyclophosph/doxorubic/vincrist/prednis"]}],"arms":[{"label":"R-HDS","type":"EXPERIMENTAL"},{"label":"R-CHOP","type":"ACTIVE_COMPARATOR"}],"summary":"Multicentric randomized phase III study comparing high doses of chemotherapy with Rituximab followed by auto-transplant HPC versus CHOP plus Rituximab as first line therapy in high risk patients with DLBCL Non-Hodgkin's lymphomas.","primaryOutcome":{"measure":"Event Free Survival","timeFrame":"36 months from end of therapy","effectByArm":[{"arm":"R-HDS","deltaMin":65,"sd":null},{"arm":"R-CHOP 14","deltaMin":62,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.05"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":16,"countries":["Italy"]},"refs":{"pmids":["32817282"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":29,"n":113},"commonTop":[]}}